CLDN18 and gastric cancer: Additionally, rare occurrences were noted in this large cohort, including CLDN18.2-positive/PD-L1-positive/EBV-positive/HER2-positive GC, PD-L1-positive/EBV-positive/FGFR2-positive GC, PD-L1-positive/EBV-positive/HER2-positive GC, and PD-L1-positive/FGFR-positive/HER2-positive GC, with each observed in only one case among the 1000 cases of GC.